S
Stockadora
IPO Journey

VivoSim Labs, INC.

IPO Date: April 2, 2026 · 3 filings tracked

Final Offer Terms

Ticker
VIVS
Exchange
Nasdaq Capital Market
Offer Price
$1.14
Shares Offered
3,508,772
Estimated Proceeds
$4.0M
Underwriters

Led by Joseph Gunnar & Co., LLC

Filing Timeline

1
S-1
March 27, 2026
  • Pioneering bioprinting technology creating 3D human liver and intestinal tissue models.
  • High accuracy rates: 87.5% for identifying toxic drugs and 100% for safe ones.
View full analysis → SEC filing ↗
2
S-1/A
March 31, 2026
  • Pioneering 'digital biology' with 3D human tissue models for drug safety testing
  • Proven liver-testing platform with 87.5% accuracy in identifying liver-toxic drugs
View full analysis → SEC filing ↗
424B4 Final Pricing
April 2, 2026
  • Pioneering 'digital biology' through 3D human tissue models for drug testing
  • Provides a scalable alternative to traditional animal testing for pharma clients

Changes from previous filing

  • ▸ Final offer price: $1.14 per share
  • ▸ Shares offered: 3,508,772
  • ▸ Estimated proceeds: $4M
View full analysis → SEC filing ↗
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.